Key Highlights

  • CLRO shares rose approximately 100% in trading today to $14.00, up from a prior close of $7.00.
  • ClearOne previously announced a definitive merger agreement with Cortigent, a wholly-owned subsidiary of Vivani Medical.
  • Upon closing, Vivani is expected to own between 59.4% and 67.5% of the combined company.
  • The combined company will be renamed Cortigent Holdings and is expected to trade under the ticker CRGT.

Merger with Neurostimulation Developer Advances

ClearOne, Inc. (NASDAQ:CLRO) shares surged in trading today as investor interest built around the company's pending merger with Cortigent, a developer of brain implant devices designed to help patients recover sight and motor function. ClearOne is a Salt Lake City-based company that recently divested its former conferencing, collaboration, and network streaming business, positioning itself for the transaction with Cortigent.

Under the merger agreement, Vivani Medical, which owns Cortigent, will receive 12,500,000 shares of ClearOne common stock as consideration, with Vivani expected to own between 59.4% and 67.5% of the combined company following closing. ClearOne has also agreed to raise a minimum of $10 million and a maximum of $15 million in connection with the transaction, with closing conditioned on completion of that financing and other customary requirements.

Cortigent Pipeline and Transaction Structure

Cortigent's predecessor, Second Sight Medical Products, previously marketed the Argus II, the first medical device to receive FDA approval for treating a rare form of blindness. The company's next-generation Orion cortical stimulation system, designed to treat blindness caused by glaucoma and diabetic retinopathy, has received FDA Breakthrough Device Designation and has completed a six-year early feasibility study. Cortigent is also applying its neurostimulation technology to improving arm and hand motion recovery in stroke patients with partial paralysis.

The transaction has been unanimously approved by the boards of both companies and is expected to close in the third quarter of 2026, subject to stockholder approvals and other customary closing conditions. ClearOne carries a market capitalization of approximately $24.38 million following today's gain, with shares trading within a 52-week range of $2.71 to $16.29.

Conclusion

Today's sharp gain reflects investor enthusiasm around the pending combination with a clinical-stage neurostimulation developer carrying an FDA Breakthrough Device Designation, though the transaction remains subject to financing and stockholder approval before it can close. Investors will likely watch for progress on the required financing and stockholder votes as the deal moves toward its expected third-quarter close.

FAQs

This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own research before making financial decisions.